Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/15/2025

Contraception Guidance for Patients with Medical Conditions

Introduction to Contraceptive Options

  • Patients with Wolff-Parkinson-White syndrome should avoid estrogen-containing contraceptives due to the increased risk of thromboembolic events that could trigger life-threatening arrhythmias, according to the American College of Cardiology 1
  • The American College of Cardiology/American Heart Association guidelines state that estrogen-containing contraceptives are potentially harmful for women with cardiac conditions at high risk of thromboembolic events, such as those with Wolff-Parkinson-White syndrome 1

Intrauterine Devices and Progestin-only Methods

  • Copper IUDs are highly effective and have no hormonal component, making them a suitable option for patients with Wolff-Parkinson-White syndrome, as stated by the European Society of Cardiology 2
  • Levonorgestrel-releasing IUDs are highly effective and have localized progestin action, providing an alternative for patients with Wolff-Parkinson-White syndrome, according to the European Society of Cardiology 2
  • Progestin-only pills are a recommended contraceptive option for patients with Wolff-Parkinson-White syndrome, as they minimize hormone-related cardiovascular risks, according to the American College of Cardiology 1, 3
  • Subdermal implants and injectable progestins (with caution regarding fluid retention) are also suitable progestin-only methods for patients with Wolff-Parkinson-White syndrome, as stated by the European Society of Cardiology 2

Special Considerations for Thrombotic Risk

  • Progestin-only pills (POPs) like norethindrone do not increase the risk of deep vein thrombosis (DVT), while combined oral contraceptives (COCs) are associated with a 2-6 fold increased risk of venous thromboembolism, according to the American College of Cardiology and supported by the U.S. Medical Eligibility Criteria 4, 5
  • The U.S. Medical Eligibility Criteria for Contraceptive Use classifies POPs as Category 2 (benefits generally outweigh risks) for women with a history of DVT/PE, compared to Category 3 or 4 (risks generally outweigh benefits or unacceptable health risk) for COCs, highlighting the importance of considering individual risk factors when selecting a contraceptive method 5
  • Women with multiple risk factors (obesity, smoking, immobility, inherited thrombophilia) have substantially higher risk of DVT/VTE, and should be assessed for baseline VTE risk, including personal or family history of VTE, known thrombophilia, age, obesity, smoking status, and immobility or recent surgery, as advised by the American College of Cardiology and the U.S. Medical Eligibility Criteria 4, 5
  • The combination of nicotine vaping and estrogen exposure increases the risk of venous thrombosis, particularly in individuals with a history of estrogen therapy, with a 2-5 fold increased risk compared to non-users, highlighting the importance of considering lifestyle factors when assessing thrombotic risk, as reported by the American Family Physician and the Journal of the National Comprehensive Cancer Network 6, 7

Estrogen Formulations and Thrombotic Risk

  • Transdermal estrogen is preferred over oral formulations due to its lower thrombosis risk (OR 4.0; 95% CI 1.9-8.3) for individuals who vape and require estrogen therapy, as supported by the American College of Obstetricians and Gynecologists, with the lowest effective estrogen dose recommended to minimize VTE risk 6, 8
  • The following table summarizes the estimated risk of VTE associated with different estrogen formulations:
Estrogen Formulation Estimated Risk of VTE
Transdermal Estrogen Lower risk (OR 4.0; 95% CI 1.9-8.3)
Oral Estrogen Higher risk (2-6 fold increase)
Combined Oral Contraceptives 2-6 fold increase in VTE risk

Monitoring and Contraceptive Recommendations

  • Women using oral contraception should be monitored for signs of DVT (unilateral leg swelling, pain, warmth) and should discontinue immediately if DVT is suspected, as recommended by the U.S. Medical Eligibility Criteria, with close monitoring and prompt action crucial in preventing adverse outcomes 5
  • Contraceptive recommendation based on risk should be considered, with low risk women having either mini pill or COC as acceptable options, moderate risk women considering mini pill (norethindrone) as first choice, and high risk women having mini pill strongly preferred and COCs contraindicated, as supported by the American College of Cardiology and the U.S. Medical Eligibility Criteria 4, 5